Advertisement
Canada markets close in 8 minutes
  • S&P/TSX

    22,221.27
    +267.47 (+1.22%)
     
  • S&P 500

    5,537.02
    +28.01 (+0.51%)
     
  • DOW

    39,308.00
    -23.85 (-0.06%)
     
  • CAD/USD

    0.7334
    +0.0023 (+0.31%)
     
  • CRUDE OIL

    83.88
    +1.07 (+1.29%)
     
  • Bitcoin CAD

    81,501.21
    -2,841.59 (-3.37%)
     
  • CMC Crypto 200

    1,254.57
    -80.35 (-6.02%)
     
  • GOLD FUTURES

    2,369.40
    +36.00 (+1.54%)
     
  • RUSSELL 2000

    2,036.62
    +2.75 (+0.14%)
     
  • 10-Yr Bond

    4.3550
    -0.0810 (-1.83%)
     
  • NASDAQ

    18,188.30
    +159.54 (+0.88%)
     
  • VOLATILITY

    12.09
    +0.06 (+0.50%)
     
  • FTSE

    8,171.12
    +49.92 (+0.61%)
     
  • NIKKEI 225

    40,580.76
    +506.07 (+1.26%)
     
  • CAD/EUR

    0.6797
    -0.0003 (-0.04%)
     

Stocks in play: Sernova Corp.

Announces developments in its Phase I/II clinical trial investigating a novel treatment for Type 1 Diabetes (T1D). To date a total of seven patients across Cohorts 1 and 2 have achieved insulin independence following transplants of human donor islets via Sernova’s proprietary Cell Pouch System™ and a marginal portal vein top up. Additionally, the study, which is being conducted at the University of Chicago, completed full enrollment of the second cohort of patients with the last patient being enrolled June 24. Sernova Corp. shares T.SVA are trading up $0.02 at $0.39.

Read: